{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:38:17Z","timestamp":1793291897105,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004088","name":"Kowa Life Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006513","name":"Duke Clinical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011421","name":"Sanofi China Investment Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014384","name":"Amarin Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003103","name":"Bundesamt f\u00fcr Strassen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003449","name":"Green Lane Research and Educational Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ahj.2020.04.004","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T23:06:43Z","timestamp":1587164803000},"page":"97-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels &lt; 70 mg\/dL and glycosylated hemoglobin A1c &lt;\u202f7% are associated with lower major cardiovascular events"],"prefix":"10.1016","volume":"225","author":[{"given":"Harvey D.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.H.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Dalby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Stebbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Budaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Krug-Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S.","family":"Hochman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ahj.2020.04.004_bb0005","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.ahj.2020.04.004_bb0010","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.ahj.2020.04.004_bb0015","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ahj.2020.04.004_bb0020","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.ahj.2020.04.004_bb0025","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2020.04.004_bb0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ahj.2020.04.004_bb0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ahj.2020.04.004_bb0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2015.06.019","article-title":"Comprehensive cardiovascular risk factor control improves survival: the BARI 2D trial","volume":"66","author":"Bittner","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2020.04.004_bb0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes","volume":"68","author":"Bansilal","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2020.04.004_bb0050","first-page":"412","article-title":"Excess mortality and guideline-indicated care following non\u2013ST-elevation myocardial infarction","volume":"6","author":"Dondo","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"41","key":"10.1016\/j.ahj.2020.04.004_bb0055","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/eurheartj\/ehx515","article-title":"Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014","volume":"38","author":"Szummer","year":"2017","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ahj.2020.04.004_bb0060","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jacc.2013.09.053","article-title":"Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry)","volume":"63","author":"Maddox","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2020.04.004_bb0065","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2337\/dc12-2258","article-title":"The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010","volume":"36","author":"Stark Casagrande","year":"2013","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1016\/j.ahj.2020.04.004_bb0070","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.2011.601","article-title":"Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention","volume":"305","author":"Borden","year":"2011","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ahj.2020.04.004_bb0075","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jacc.2013.01.044","article-title":"Risk factor control for coronary artery disease secondary prevention in large randomized trials","volume":"61","author":"Farkouh","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2020.04.004_bb0080","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/2047487312444995","article-title":"Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study","volume":"20","author":"Vedin","year":"2013","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2020.04.004_bb0085","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2010.07.006","volume":"160","author":"White","year":"2010","journal-title":"Am Heart J"},{"issue":"18","key":"10.1016\/j.ahj.2020.04.004_bb0090","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"White","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2020.04.004_bb0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahj.2020.04.004_bb0100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2008.10.008","volume":"53","author":"Skyler","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2020.04.004_bb0105","first-page":"S11","volume":"35","author":"Standards of medical care in diabetes--2012","year":"2012","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1016\/j.ahj.2020.04.004_bb0110","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ahj.2020.04.004_bb0115","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"issue":"7329","key":"10.1016\/j.ahj.2020.04.004_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"9753","key":"10.1016\/j.ahj.2020.04.004_bb0125","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ahj.2020.04.004_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2020.04.004_bb0135","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"issue":"25","key":"10.1016\/j.ahj.2020.04.004_bb0140","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2020.04.004_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.ahj.2020.04.004_bb0150","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ahj.2020.04.004_bb0155","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ahj.2020.04.004_bb0160","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ahj.2020.04.004_bb0165","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.ahj.2020.04.004_bb0170","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2020.04.004_bb0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ahj.2020.04.004_bb0180","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ahj.2020.04.004_bb0185","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ahj.2020.04.004_bb0190","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jamacardio.2019.0649","article-title":"Effect of a multifaceted quality improvement intervention on the prescription of evidence-based treatment in patients at high cardiovascular risk in Brazil: the BRIDGE cardiovascular prevention cluster randomized clinical trial","volume":"4","author":"Machline-Carrion","year":"2019","journal-title":"JAMA cardiology"},{"issue":"16","key":"10.1016\/j.ahj.2020.04.004_bb0195","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2018.11.067","article-title":"Lifestyle, glycosylated hemoglobin A1c, and survival among patients with stable ischemic heart disease and diabetes","volume":"73","author":"Mancini","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ahj.2020.04.004_bb0200","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2018.12.091","article-title":"Lifestyle interventions in diabetes and coronary disease: a timely reminder","volume":"73","author":"Farkouh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.04.004_bb0205","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.04.004_bb0210","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries\u2014findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1511","key":"10.1016\/j.ahj.2020.04.004_bb0215","first-page":"21","article-title":"Utilisation and maintenance of high-intensity statins following acute coronary syndrome and coronary angiography: opportunities to improve care (ANZACS-QI 26)","volume":"133","author":"Kerr","year":"2020","journal-title":"N Z Med J"},{"issue":"1","key":"10.1016\/j.ahj.2020.04.004_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/heartasia-2018-011122","article-title":"Secondary prevention therapies in acute coronary syndrome and relation to outcomes: observational study","volume":"11","author":"Chow","year":"2019","journal-title":"Heart Asia"},{"issue":"15","key":"10.1016\/j.ahj.2020.04.004_bb0225","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.108.824151","article-title":"Statin adherence and risk of accidents: a cautionary tale","volume":"119","author":"Dormuth","year":"2009","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:26Z","timestamp":1762077446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320301101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":45,"alternative-id":["S0002870320301101"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.04.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg\/dL and glycosylated hemoglobin A1c <\u202f7% are associated with lower major cardiovascular events","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}